These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 18541383)
21. Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease. Bharathi ; Rao KS Biochem Biophys Res Commun; 2007 Jul; 359(1):115-20. PubMed ID: 17531952 [TBL] [Abstract][Full Text] [Related]
22. Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages. Ichibangase T; Saimaru H; Takamura N; Kuwahara T; Koyama A; Iwatsubo T; Imai K Biomed Chromatogr; 2008 Mar; 22(3):232-4. PubMed ID: 17939164 [TBL] [Abstract][Full Text] [Related]
23. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Emmanouilidou E; Stefanis L; Vekrellis K Neurobiol Aging; 2010 Jun; 31(6):953-68. PubMed ID: 18715677 [TBL] [Abstract][Full Text] [Related]
24. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Yavich L; Oksman M; Tanila H; Kerokoski P; Hiltunen M; van Groen T; Puoliväli J; Männistö PT; García-Horsman A; MacDonald E; Beyreuther K; Hartmann T; Jäkälä P Neurobiol Dis; 2005 Nov; 20(2):303-13. PubMed ID: 16242637 [TBL] [Abstract][Full Text] [Related]
25. Characterization of inhibitor-bound alpha-synuclein dimer: role of alpha-synuclein N-terminal region in dimerization and inhibitor binding. Yamaguchi Y; Masuda M; Sasakawa H; Nonaka T; Hanashima S; Hisanaga S; Kato K; Hasegawa M J Mol Biol; 2010 Jan; 395(3):445-56. PubMed ID: 19895818 [TBL] [Abstract][Full Text] [Related]
26. On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and lacmoid. Lendel C; Bertoncini CW; Cremades N; Waudby CA; Vendruscolo M; Dobson CM; Schenk D; Christodoulou J; Toth G Biochemistry; 2009 Sep; 48(35):8322-34. PubMed ID: 19645507 [TBL] [Abstract][Full Text] [Related]
27. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein. Marxreiter F; Nuber S; Kandasamy M; Klucken J; Aigner R; Burgmayer R; Couillard-Despres S; Riess O; Winkler J; Winner B Eur J Neurosci; 2009 Mar; 29(5):879-90. PubMed ID: 19291219 [TBL] [Abstract][Full Text] [Related]
28. Cu2+ binding modes of recombinant alpha-synuclein--insights from EPR spectroscopy. Drew SC; Leong SL; Pham CL; Tew DJ; Masters CL; Miles LA; Cappai R; Barnham KJ J Am Chem Soc; 2008 Jun; 130(24):7766-73. PubMed ID: 18494470 [TBL] [Abstract][Full Text] [Related]
29. Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity. Wang X; Moualla D; Wright JA; Brown DR J Neurochem; 2010 May; 113(3):704-14. PubMed ID: 20141569 [TBL] [Abstract][Full Text] [Related]
30. Alpha-synuclein and its role in metal binding: relevance to Parkinson's disease. Wright JA; Brown DR J Neurosci Res; 2008 Feb; 86(3):496-503. PubMed ID: 17705291 [TBL] [Abstract][Full Text] [Related]
31. Effects of nitration on the structure and aggregation of alpha-synuclein. Uversky VN; Yamin G; Munishkina LA; Karymov MA; Millett IS; Doniach S; Lyubchenko YL; Fink AL Brain Res Mol Brain Res; 2005 Mar; 134(1):84-102. PubMed ID: 15790533 [TBL] [Abstract][Full Text] [Related]
32. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein. Heise H; Celej MS; Becker S; Riedel D; Pelah A; Kumar A; Jovin TM; Baldus M J Mol Biol; 2008 Jul; 380(3):444-50. PubMed ID: 18539297 [TBL] [Abstract][Full Text] [Related]
33. Binding of Cu(II) to human alpha-synucleins: comparison of wild type and the point mutations associated with the familial Parkinson's disease. Hong L; Simon JD J Phys Chem B; 2009 Jul; 113(28):9551-61. PubMed ID: 19548659 [TBL] [Abstract][Full Text] [Related]
34. Alpha-synuclein multistate folding thermodynamics: implications for protein misfolding and aggregation. Ferreon AC; Deniz AA Biochemistry; 2007 Apr; 46(15):4499-509. PubMed ID: 17378587 [TBL] [Abstract][Full Text] [Related]
36. Protein interactions and misfolding analyzed by AFM force spectroscopy. McAllister C; Karymov MA; Kawano Y; Lushnikov AY; Mikheikin A; Uversky VN; Lyubchenko YL J Mol Biol; 2005 Dec; 354(5):1028-42. PubMed ID: 16290901 [TBL] [Abstract][Full Text] [Related]
37. Controlling the mass action of alpha-synuclein in Parkinson's disease. Kim C; Lee SJ J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382 [TBL] [Abstract][Full Text] [Related]
38. Specificity determinants on Cdc42 for binding its effector protein ACK. Elliot-Smith AE; Mott HR; Lowe PN; Laue ED; Owen D Biochemistry; 2005 Sep; 44(37):12373-83. PubMed ID: 16156650 [TBL] [Abstract][Full Text] [Related]
39. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459 [TBL] [Abstract][Full Text] [Related]
40. PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein. Rekas A; Lo V; Gadd GE; Cappai R; Yun SI Macromol Biosci; 2009 Mar; 9(3):230-8. PubMed ID: 19116892 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]